These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31516397)

  • 1. Why we should take care of the competing risk bias in survival analysis: A phase II trial on the toxicity profile of radiotherapy for prostate cancer.
    Tullio A; Magli A; Moretti E; Valent F
    Rep Pract Oncol Radiother; 2019; 24(6):511-519. PubMed ID: 31516397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling competing risks in nephrology research: an example in peritoneal dialysis.
    Teixeira L; Rodrigues A; Carvalho MJ; Cabrita A; Mendonça D
    BMC Nephrol; 2013 May; 14():110. PubMed ID: 23705871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. Basic concepts and first analyses.
    Tai BC; Grundy RG; Machin D
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1493-9. PubMed ID: 19577860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates.
    Nolan EK; Chen HY
    Arch Osteoporos; 2020 Jun; 15(1):86. PubMed ID: 32519193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account.
    Evans DW; Ryckelynck JP; Fabre E; Verger C
    Nephrol Dial Transplant; 2010 Jul; 25(7):2315-22. PubMed ID: 20103502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation and comparison of cumulative incidences of biliary self-expandable metallic stent dysfunction accounting for competing risks.
    Hamada T; Nakai Y; Isayama H; Togawa O; Kogure H; Kawakubo K; Tsujino T; Sasahira N; Hirano K; Yamamoto N; Ito Y; Sasaki T; Mizuno S; Toda N; Tada M; Koike K
    Dig Endosc; 2014 Mar; 26(2):270-5. PubMed ID: 23650933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism.
    Parpia S; Julian JA; Thabane L; Lee AY; Rickles FR; Levine MN
    Contemp Clin Trials; 2011 Nov; 32(6):829-33. PubMed ID: 21777700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method.
    Zhu X; Kranse R; Bul M; Bangma CH; Schröder FH; Roobol MJ
    Can J Urol; 2013 Jun; 20(3):6756-60. PubMed ID: 23783043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation.
    Abdel-Qadir H; Fang J; Lee DS; Tu JV; Amir E; Austin PC; Anderson GM
    Circ Cardiovasc Qual Outcomes; 2018 Jul; 11(7):e004580. PubMed ID: 29997149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different survival analysis methods for measuring long-term outcomes of Indigenous and non-Indigenous Australian cancer patients in the presence and absence of competing risks.
    He VY; Condon JR; Baade PD; Zhang X; Zhao Y
    Popul Health Metr; 2017 Jan; 15(1):1. PubMed ID: 28095862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis.
    Schuster NA; Hoogendijk EO; Kok AAL; Twisk JWR; Heymans MW
    J Clin Epidemiol; 2020 Jun; 122():42-48. PubMed ID: 32165133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in patients with gastric adenocarcinoma using competing-risk analysis: a study of cases in the SEER database.
    Zhang X; Yang J; Huang Q; Lyu J
    Scand J Gastroenterol; 2019 Aug; 54(8):1015-1021. PubMed ID: 31382800
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing risk factors of non-fatal outcomes amid a competing risk of mortality: the example of hip fracture.
    Buzkova P; Barzilay JI; Mukamal KJ
    Osteoporos Int; 2019 Oct; 30(10):2073-2078. PubMed ID: 31256203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram to Predict Cause-Specific Mortality in Patients With Surgically Resected Stage I Non-Small-Cell Lung Cancer: A Competing Risk Analysis.
    Zhou H; Zhang Y; Qiu Z; Chen G; Hong S; Chen X; Zhang Z; Huang Y; Zhang L
    Clin Lung Cancer; 2018 Mar; 19(2):e195-e203. PubMed ID: 29153966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomogram to predict cause-specific mortality of patients with rectal adenocarcinoma undergoing surgery: a competing risk analysis.
    Zhang X; Xu F; Bin Y; Liu T; Li Z; Guo D; Li Y; Huang Q; Lyu J; He S
    BMC Gastroenterol; 2022 Feb; 22(1):57. PubMed ID: 35144545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tree-based models for survival data with competing risks.
    Kretowska M
    Comput Methods Programs Biomed; 2018 Jun; 159():185-198. PubMed ID: 29650312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of competing-risks setting on the choice of hypothesis test for treatment effect.
    Williamson PR; Kolamunnage-Dona R; Tudur Smith C
    Biostatistics; 2007 Oct; 8(4):689-94. PubMed ID: 17151088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine-Gray subdistribution hazard models to simultaneously estimate the absolute risk of different event types: Cumulative total failure probability may exceed 1.
    Austin PC; Steyerberg EW; Putter H
    Stat Med; 2021 Aug; 40(19):4200-4212. PubMed ID: 33969508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.